Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 73.72% is in line with its 5-year average of 71.71%, near the high end of its 5-year range (67.37%–75.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.01% above its 12-month average of 73.71%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
73.72%
GROSS MARGIN AVG TTM
73.71%
GROSS MARGIN AVG 3Y
73.01%
GROSS MARGIN AVG 5Y
71.71%
GROSS MARGIN AVG 10Y
71.76%
GROSS MARGIN AVG 15Y
72.29%
GROSS MARGIN AVG 20Y
72.12%
CURRENT VS TTM AVG
+0.01%
CURRENT VS 3Y AVG
+0.97%
CURRENT VS 5Y AVG
+2.79%
CURRENT VS 10Y AVG
+2.72%
CURRENT VS 15Y AVG
+1.97%
CURRENT VS 20Y AVG
+2.21%
SECTOR MEDIAN · HEALTHCARE
61.16%
median of 85 covered companies
CURRENT VS SECTOR MEDIAN
+20.53%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
Gross Margin
73.72%
TTM Avg
73.71%
3Y Avg
73.01%
5Y Avg
71.71%
Market Cap
$358.76B
Gross Margin
22.49%
TTM Avg
20.43%
3Y Avg
22.48%
5Y Avg
23.36%
Market Cap
$369.34B
Gross Margin
75.38%
TTM Avg
74.15%
3Y Avg
73.03%
5Y Avg
71.89%
Market Cap
$234.38B
Gross Margin
40.37%
TTM Avg
39.50%
3Y Avg
40.36%
5Y Avg
43.54%
Market Cap
$205.42B
Gross Margin
80.64%
TTM Avg
82.83%
3Y Avg
83.54%
5Y Avg
83.48%
Market Cap
$193.04B
Gross Margin
56.80%
TTM Avg
53.17%
3Y Avg
51.86%
5Y Avg
51.92%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 73.72% | 73.71% | 73.01% | 71.71% |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 22.49% | 20.43% | 22.48% | 23.36% |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 75.38% | 74.15% | 73.03% | 71.89% |
| AbbVie Inc. (ABBV)vs › | $455.87B | 71.48% | 70.11% | 68.16% | 68.00% |
| AstraZeneca PLC (AZN)vs › | $255.15B | 81.88% | 81.51% | 79.26% | 77.31% |
| Amgen Inc. (AMGN)vs › | $235.85B | 72.65% | 66.16% | 69.53% | 71.51% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 40.37% | 39.50% | 40.36% | 43.54% |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 80.64% | 82.83% | 83.54% | 83.48% |
| Abbott Laboratories (ABT)vs › | $193.04B | 56.80% | 53.17% | 51.86% | 51.92% |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 79.59% | 78.55% | 78.10% | 78.28% |
Gross Margin
73.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 73.72% |
| 2025-12-31 | 71.74% |
| 2025-06-30 | 75.67% |
| 2024-12-31 | 72.15% |
| 2024-06-30 | 75.71% |
| 2023-12-31 | 67.37% |
| 2023-06-30 | 74.69% |
| 2022-12-31 | 70.67% |
| 2022-06-30 | 69.81% |
| 2021-12-31 | 67.38% |
| 2021-06-30 | 69.92% |
| 2020-12-31 | 70.89% |
| 2020-06-30 | 73.00% |
| 2019-12-31 | 70.68% |
| 2019-06-30 | 73.38% |
| 2018-12-31 | 71.06% |
| 2018-06-30 | 73.43% |
| 2017-12-31 | 70.87% |
| 2017-06-30 | 72.14% |
| 2016-12-31 | 70.59% |
| 2016-06-30 | 72.14% |
| 2015-12-31 | 71.43% |
| 2015-06-30 | 72.05% |
| 2014-12-31 | 72.88% |
| 2014-06-30 | 75.12% |
| 2013-12-31 | 74.19% |
| 2013-06-30 | 74.88% |
| 2012-12-31 | 75.04% |
| 2012-06-30 | 73.24% |
| 2011-12-31 | 73.24% |
| 2011-06-30 | 71.92% |
| 2010-12-31 | 71.92% |
| 2010-06-30 | 72.00% |
| 2009-12-31 | 72.00% |
| 2009-06-30 | 70.20% |
| 2008-12-31 | 70.05% |
| 2008-06-30 | 70.05% |
| 2007-12-31 | 70.05% |
| 2007-06-30 | 70.21% |
| 2006-12-31 | 74.75% |
| 2006-06-30 | 74.75% |
| 2005-12-31 | 73.80% |
| 2005-06-30 | 73.80% |
| 2004-12-31 | 73.80% |
| 2004-06-30 | 77.03% |
| 2003-12-31 | 73.37% |
| 2003-06-30 | 73.37% |
| 2002-12-31 | 71.63% |
| 2002-06-30 | 71.63% |
| 2001-12-31 | 71.41% |
| 2001-06-30 | 71.41% |
| 2000-12-31 | 68.04% |
| 2000-06-30 | 68.04% |
| 1999-12-31 | 67.81% |
| 1999-06-30 | 67.81% |
| 1998-12-31 | 67.81% |
| 1998-06-30 | 67.96% |
| 1998-01-31 | 67.96% |
